Apogee Announces Formation of Medical Advisory Board.
Herbert Stein, Apogee's Chairman and Chief Executive Officer, said, "We believe this esteemed board will provide the technical oversight to help us effectively transition our MEMS based transdermal delivery products from research, through development, clinical testing and product approval and release. Dr. Peter Carroll has been appointed chairman of the advisory board. He has a Ph.D. in immunology and is the founder of Medlen & Carroll, LLP, a biotechnology patent law firm. He is joined by Dr. Joachim Kohn, an expert in controlled drug delivery and the current Director of the New Jersey Center for Biomaterials, and Dr. Sanford Simon, Professor of Biochemistry, Cell Biology and Pathology at Stony Brook University and who is involved in research programs related to cell biology and the development of vaccines and other therapeutics."
Dr. Peter G. Carroll, Esq. has approximately ten years of experience in basic scientific research (1977-1979 Sidney Farber Cancer Institute; 1979-1983 Tufts Sackler School of Graduate Studies; 1983-1984 Eunice Kennedy Schriver Center) as well as significant experience in commercial research and development (1984-1986 Travenol-Genentech Diagnostics, Inc.). He also has seven years of hands on medical laboratory experience (1980-1987 New England Medical Center). From 1991 to 1993, Dr. Carroll was Vice President of Commercial Development of a biotechnology startup, now known as Cerus Corporation, a company formed to address the commercial need for solutions to blood contamination. Dr. Carroll is the founder of his own biotechnology patent law firm, Medlen & Carroll, LLP, with offices in California, Massachusetts, New York, Texas and Wisconsin.
Dr. Joachim Kohn is a Board of Governors Professor of Chemistry and Chemical Biology at Rutgers and an Adjunct Associate Professor of Orthopedics at the New Jersey Medical School. He currently serves as director of the New Jersey Center for Biomaterials. He is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and served as the secretary-treasurer of the Society for Biomaterials. He is the principal investigator of an NIH funded postdoctoral training program in tissue engineering and implant science. His research interests focus on the development of new biomaterials for prostheses, implantable drugs, gene delivery systems and tissue regeneration scaffolds. He has published 200 scientific manuscripts and reviews, and is listed as an inventor on 37 patents.
Dr. Sanford R. Simon has over 40 years' of experience in biochemistry and cell biology as well as applied genetic research. He has been a Professor of Biochemistry, Cell Biology and Pathology at Stony Brook since 1997. He joined the faculty at Stony Brook as an Assistant Professor in 1969 and was promoted to Associate Professor with tenure in 1975. Dr. Simon was a member of the Board of Directors of The Collaborative Group from 1995 to 2004. From 1967 to 1969 Dr. Simon was a Guest Investigator at Rockefeller University. Dr. Simon received a B.A. in Zoology and Chemistry from Columbia University in 1963, a Ph.D. in Biochemistry from Rockefeller University in 1967, and studied as a postdoctoral fellow with Nobel Prize winner Max Perutz in Cambridge, England. Dr. Simon's research efforts, which currently include development of vaccines and small molecule therapeutics for biodefense applications, have been funded over the past several years in part by grants from the National Institutes of Health and the Department of Defense. Dr. Simon is also the principal investigator on a project entitled "A Chimeric Method and System for DNA Encryption and Authentication", which is funded jointly by APDN, Stony Brook's Center for Biotechnology and the New York State Office of Science, Technology and Academic Research.
About Apogee Technology, Inc.
Apogee Technology designs, develops and markets proprietary sensor and medical device products using its MEMS and nanotechnology for the automotive, industrial, consumer and medical markets. The Company has introduced a family of pressures sensors, under the Sensilica(TM) brand and is currently developing a MEMS based medical device for enhanced transdermal drug delivery. Apogee has significant experience in bringing high-performance and high volume MEMS components to market quickly. Our objective is to provide value-added and cost-savings solutions for our customers, and in so doing, to become a global leader in the field. The Company operates a worldwide marketing and sales organization and has offices in the US and Japan. For more information please visit our web site at: http://www.apogeemems.com.
Sensilica(TM) is a trademark of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "hope," "estimate," "project," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.
|Printer friendly Cite/link Email Feedback|
|Date:||May 12, 2006|
|Previous Article:||Petrosearch Announces Agreement Defining Terms of Participation in the Barnett Shale Project.|
|Next Article:||Segmentz, Inc. Reports Continued Growth and Profitability in the First Quarter of 2006; Expedited Transportation Revenue Rises 20 Percent; Gross...|